Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“In this trial, omalizumab significantly reduced dose-related symptoms and OIT-related side effects, including a reduction in treatments with epinephrine (7).”